Furthermore, ongoing research aims to elucidate the complex interactions between VEGFR signaling and the tumor microenvironment, highlighting the VEGF/VEGFR pathway as a significant regulator of the TME and supporting the potential benefits of combining VEGF/VEGFR inhibition with immune checkpoint therapy [86]. This evidence concerns the gene VEGFA and neoplasm.